Roche has announced the approval of Tecentriq (atezolizumab), in combination with Celgene’s chemotherapy drug Abraxane (nab paclitaxel), by the European Medicines Agency in the treatment of PD-L1-positive, unresectable locally advanced or metastatic triple-negative breast cancer, making it the first immunotherapy regimen available in the continent for this indication.
